Stella Diagnostics

Stella Diagnostics, Inc. is a molecular diagnostics-based organization dedicated to improving patient management strategies for over 67 million patients with severe esophageal diseases. Stella Diagnostics' mass spectrometry proteomics assay provides doctors with insight into the molecular characteristics of patient tissues, determining whether the disease is stable, progressing, or becoming cancerous. The company's diagnostic aim is to provide a first-line diagnostic tool that delivers superior molecular information to providers compared to current standard screening protocols, with the goal of establishing a research-based organization that offers clinically actionable diagnostic panels for the current disease state of the patient’s distal esophagus.